• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Mark Zimmerman on How Depression Severity Is Measured

Video

Most commonly, depression severity is measured by instruments that focus on the symptoms of depression, said Mark Zimmerman, MD, director of outpatient psychiatry and the Partial Hospital Program at Rhode Island Hospital, and a professor of psychiatry at Brown Medical School.

Mark Zimmerman, MD, director of outpatient psychiatry and the Partial Hospital Program at Rhode Island Hospital, and a professor of psychiatry at Brown Medical School.

Transcript

How are different levels of depression severity measured?

Most commonly, depression severity is measured by instruments that focus on the symptoms of depression, and then there are graded levels of severity, That’s the predominance in the research literature. It differs, though, from how severity of depression is defined in DSM-5, the diagnostic and statistical manual. In the DSM-5, as well as the international classifications of diseases, the ICD, there are multiple constructs that are considered in assessing the severity of depression. One is the number of symptoms, which is similar to scales. But, another consideration is the distress that symptoms cause.

A third consideration is the impairment caused by the symptoms of depression. So, there is this disconnect between how DSM-5 and ICD-10 consider classifying depression severity and how researchers, almost universally, measure the severity of depression.

Related Videos
Ivo Carre, PhD
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute
Ivo Carre, PhD, senior business analyst, Lifescience Dynamics
AHA 2025 recap layered on photo of Bourbon Street in New Orleans | Image credit: SeanPavonePhoto - stock.adobe.com
Screenshot of an interview with Stephen Nicholls, MBBS, PhD
Screenshot of an interview with Roy Mathew, MD
Screenshot of an interview with Vallerie McLaughlin, MD
Oncology experts at PCOC
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.